

## FDA permits marketing of test to detect periprosthetic joint infection

May 29 2019



(HealthDay)—The Synovasure Lateral Flow Test Kit was granted



approval for marketing as an aid in detecting periprosthetic joint infection when evaluating patients for revision surgery, the U.S. Food and Drug Administration announced.

Tim Stenzel, M.D., Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in the FDA Center for Devices and Radiological Health, said this <u>test</u> will help clinicians when they are assessing whether a patient should undergo revision surgery and could help to avoid unnecessary revision operations.

The Synovasure Lateral Flow Test Kit can detect human alpha defensins in patients' synovial fluid in about 10 minutes. The FDA notes that the test kit is not meant to identify a specific infection type but is an aid in determining whether infection is present. The <u>test results</u> should be used in combination with other clinical and diagnostic findings when determining diagnosis of infection.

Approval was based on <u>clinical data</u> from 305 prospective synovial fluid samples collected from patients with total knee or hip joint replacement who were being assessed for revision surgery. Researchers found that 89.5 percent of patients with an infection diagnosis based on standard-of-care criteria were also identified as positive for alpha defensins with the Synovasure Lateral Flow Test Kit.

Marketing authorization of the test kit was granted to CD Diagnostics.

**More information:** More Information

<u>Health News</u> Copyright © 2019 <u>HealthDay</u>. All rights reserved.

Citation: FDA permits marketing of test to detect periprosthetic joint infection (2019, May 29) retrieved 27 April 2024 from



https://medicalxpress.com/news/2019-05-fda-periprosthetic-joint-infection.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.